Biotechnology

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval forMagicTouch  Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

2022-09-19 12:20 1807

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

SHANGHAI and BUCKS COUNTY, Pa., Sept. 20, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines ...

2022-09-19 09:34 1532

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific ...

2022-09-19 08:00 3971

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...

2022-09-17 00:20 2327

New treatment for rare cancer cholangiocarcinoma approved in Australia

* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...

2022-09-15 21:00 1355

Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection

HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection has completed ...

2022-09-15 18:10 2193

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...

2022-09-15 17:07 1202

Austar Lifesciences Announces 2022 Interim Results

Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million  Operation Highlights (RMB'000) For the six months ended 30 June ...

2022-09-15 16:53 3405

Food Pioneers Sophie's Bionutrients And NewFish Join Forces To Develop Dairy Alternatives From Microalgae

AMSTERDAM and AUCKLAND, New Zealand, Sept. 15, 2022 /PRNewswire/ -- Sophie's Bionutrients and NewFish®, two pioneers in the field of microalgae protein fermentation, with the support ofNew Zealand-based marine research powerhouse, Cawthron Institute, andNetherlands-based leading food university, ...

2022-09-15 15:55 6496

GenScript Receives Best Cell & Gene Therapy Supplier Award: Gene Editing and GenScript ProBio Receives Best Biologics CMO Awards: Upstream Processing & Analytical Services

SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) and GenScriptProBio (a global one-stop CDMO from GenScript Group) receive 3 awards: Best Cell & Gene Therapy Supplier Award – Gene Editing on the Asia-Pacific Cell & Gene Therapy Excellence ...

2022-09-15 12:34 7243

ClavystBio launches to translate life sciences breakthroughs into health impact

* ClavystBio will invest and work with partners to accelerate life sciences  commercialisation inSingapore through three pillars: collaborate, venture and build. * ClavystBio has committed US$220 million to date in investments to launch global life sciences companies fromSingapore. SINGAPORE, ...

2022-09-15 10:00 4206

Juniper Biologics Establishes Global Headquarters in Singapore

Juniper Biologics' investment will support the growth and innovation of Singapore's pharmaceutical sector SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its ...

2022-09-15 09:53 1667

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...

2022-09-14 20:30 2273

DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY

AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr as a Non-Executive Director to the board.

2022-09-14 13:05 1104

MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS

MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventu...

2022-09-14 11:09 1095

Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022

* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...

2022-09-14 09:11 1702

GBB Lands USD 15M Pre-Series B Funding Led by Tiger Jade Capital

HONG KONG, Sept. 13, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of itsUSD 15M Pre-series B funding led by Tiger Jade Capital (hereinafter referred to as "Tiger Jade"). The funding was oversubscribed and upsized with participat...

2022-09-14 09:08 1544

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line(1L)treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...

2022-09-14 09:04 1694

Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)

* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. * The phase III pivotal study is planned to confirm the eff...

2022-09-14 09:01 1730

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...

2022-09-14 08:30 3258
1 ... 105106107108109110111 ... 275

Week's Top Stories